NCT01009788: ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer

NCT01009788
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: BRCA+
Breast Cancer Tissue: 
Recruitment Status: Active, not recruiting
Phase 2
Drug Category: Chemotherapy, Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: Patient must have at least 1 prior chemotherapy regimen for metastatic disease; Patients with HER2+ breast cancer must have progressed on prior HER2 therapy (or have contraindication); Patients with hereditary BRCA1/2 are also eligible for the expansion cohort
Exclusions: Patients with symptomatic, unstable, untreated brain metastases- see trial for details; Patients with leptomeningeal disease; Patients with prior exposure to a PARP inhibitor is allowed, but no prior exposure to PARP with a combination of chemotherapy is allowed
https://ClinicalTrials.gov/show/NCT01009788

Comments are closed.

Up ↑